Polymer-drug conjugates as nano-sized medicines

Current Opinion in Biotechnology

Volumn 22, Issue 6, 2011, Pages 894-900

  Canal, Fabiana ^a   Sanchis, Joaquin ^a   Vicent, María J ^a  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; CHARACTERIZATION TECHNIQUES; CLINICAL BIOMARKERS; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION THERAPY; MOLECULAR TARGETS; NANO-SIZED; PLATFORM TECHNOLOGY; POLYMER CHEMISTRY; POLYMER CONJUGATE; POLYMER THERAPEUTICS; POLYMER-PROTEIN CONJUGATES;

DISEASE CONTROL; DISEASES; DRUG THERAPY;

FUNCTIONAL POLYMERS;

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; ALENDRONIC ACID; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CAMPTOTHECIN; CRLX 101; CT 2106; CURCUMIN; CYCLODEXTRIN; DOXORUBICIN; ESTRADIOL; FLEXIMER; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GELDANAMYCIN; IRINOTECAN; IT 101; LIPOSOME; MAG CPT; N (2 HYDROXYPROPYL)METHACRYLAMIDE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NANOCARRIER; NANOPARTICLE; NKTR 105; NKTR 118; PACLITAXEL; PACLITAXEL POLIGLUMEX; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; PNU166945; POLY(2 ALKYLOXAZOLINE); POLYMER; PROLINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG; XMT 1001; XMT 1107;

ANTIANGIOGENIC ACTIVITY; BONE METASTASIS; CONSTIPATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RELEASE; DRUG RESEARCH; DRUG TARGETING; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; NANOBIOTECHNOLOGY; NANOMEDICINE; NONHUMAN; OVARY CANCER; PARTICLE SIZE; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; POLYMER DIRECTED ENZYME PRODRUG THERAPY; POLYMERIZATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN SYNTHESIS INHIBITION; REVIEW;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; NANOMEDICINE; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 82755193748     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2011.06.003     Document Type: Review

References (52)

1. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003, 2:347-360.
2. Duncan R, Gaspar R: Nanomedicine(s) under the microscope. NanoToday 2011, in press. http://www.ruthduncan.co.uk/%23/2011-nanomedicines-review/4551969069.
3. Vicent M.J., Ringsdorf H., Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev 2009, 61:1117-1120.
4. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
5. Vicent M.J., Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 2006, 24:39-47.
6. Vicent M.J., Dieudonne L., Carbajo R.J., Pineda-Lucena A. Polymer conjugates as therapeutics: future trends, challenges and opportunities. Expert Opin Drug Deliv 2008, 5:593-614.
7. Gaspar R., Duncan R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev 2009, 61:1220-1231.
8. Sanchis J., Canal F., Lucas R., Vicent M.J. Polymer-drug conjugates for novel molecular targets. Nanomedicine (Lond) 2010, 5:915-935.
9. Varticovski L., Lu Z.R., Mitchell K., de Aos I., Kopecek J. Water-soluble HPMA copolymer-wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo. J Control Release 2001, 74:275-281.
10. Larson N., Ray A., Malugin A., Pike D.B., Ghandehari H. HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer. Pharm Res 2010, 27:2683-2693.
11. Vicent M.J. Polymer-drug conjugates as modulators of cellular apoptosis. AAPS J 2007, 9:E200-207.
12. Li J., Wang Y., Yang C., Wang P., Oelschlager D.K., Zheng Y., Tian D.A., Grizzle W.E., Buchsbaum D.J., Wan M. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol Pharmacol 2009, 76:81-90.
13. Oman M., Liu J.H., Chen J., Durrant D., Yang H.S., He Y.W., Kopeckova P., Kopecek J., Lee R.M. Using N-(2-hydroxypropyl) methacrylamide copolymer drug bioconjugate as a novel approach to deliver a Bcl-2-targeting compound HA14-1 in vivo. Gen Ther Mol Biol 2006, 10A:113-122.
14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
15. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
16. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., Corfas G., Folkman J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004, 10:255-261.
17. Segal E., Satchi-Fainaro R. Design and development of polymer conjugates as anti-angiogenic agents. Adv Drug Deliv Rev 2009, 61:1159-1176.
18. Segal E., Pan H., Ofek P., Udagawa T., Kopeckova P., Kopecek J., Satchi-Fainaro R. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS ONE 2009, 4:e5233.
19. Miller K., Erez R., Segal E., Shabat D., Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl 2009, 48:2949-2954.
20. Eldar-Boock A., Miller K., Sanchis J., Lupu R., Vicent M.J., Satchi-Fainaro R. Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials 2011, 32:3862-3874.
21. Deacon S.P., Apostolovic B., Carbajo R.J., Schott A.K., Beck K., Vicent M.J., Pineda-Lucena A., Klok H.A., Duncan R. Polymer coiled-coil conjugates: potential for development as a new class of therapeutic "molecular switch" Biomacromolecules 2011, 12:19-27.
22. Vicent M.J., Cascales L., Carbajo R.J., Cortes N., Messeguer A., Perez Paya E. Nanoconjugates as intracorporeal neutralizers of bacterial endotoxins. J Control Release 2009, 142:277-285.
23. Santamaria B., Benito-Martin A., Ucero A.C., Aroeira L.S., Reyero A., Vicent M.J., Orzaez M., Celdran A., Esteban J., Selgas R., et al. A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury. PLoS ONE 2009, 4:e6634.
24. Liu X.M., Quan L.D., Tian J., Laquer F.C., Ciborowski P., Wang D. Syntheses of click PEG-dexamethasone conjugates for the treatment of rheumatoid arthritis. Biomacromolecules 2010, 11:2621-2628.
25. Ikumi Y., Kida T., Sakuma S., Yamashita S., Akashi M. Polymer-phloridzin conjugates as an anti-diabetic drug that inhibits glucose absorption through the Na+/glucose cotransporter (SGLT1) in the small intestine. J Control Release 2008, 125:42-49.
26. Shaunak S., Thomas S., Gianasi E., Godwin A., Jones E., Teo I., Mireskandari K., Luthert P., Duncan R., Patterson S., et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 2004, 22:977-984.
27. Mondragon L., Orzaez M., Sanclimens G., Moure A., Arminan A., Sepulveda P., Messeguer A., Vicent M.J., Perez-Paya E. Modulation of cellular apoptosis with apoptotic protease-activating factor 1 (Apaf-1) inhibitors. J Med Chem 2008, 51:521-529.
28. Pan H., Sima M., Kopeckova P., Wu K., Gao S., Liu J., Wang D., Miller S.C., Kopecek J. Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol Pharm 2008, 5:548-558.
29. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009, 61:1203-1213.
30. Dipetrillo T., Suntharalingam M., Ng T., Fontaine J., Horiba N., Oldenburg N., Perez K., Birnbaum A., Battafarano R., Burrows W., et al. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial. Am J Clin Oncol 2011, 10.1097/COC.0b013e318201a126.
31. Langer C.J., O'Byrne K.J., Socinski M.A., Mikhailov S.M., Lesniewski-Kmak K., Smakal M., Ciuleanu T.E., Orlov S.V., Dediu M., Heigener D., et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:623-630.
32. Lammers T., Subr V., Ulbrich K., Hennink W.E., Storm G., Kiessling F. Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today 2010, 5:197-212.
33. Vicent M.J., Greco F., Nicholson R.I., Paul A., Griffiths P.C., Duncan R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed Engl 2005, 44:4061-4066.
34. Chandna P., Saad M., Wang Y., Ber E., Khandare J., Vetcher A.A., Soldatenkov V.A., Minko T. Targeted proapoptotic anticancer drug delivery system. Mol Pharm 2007, 4:668-678.
35. Barz M., Luxenhofer R., Zentel R., Vicent M.J. Well-defined polymers as potential alternatives to PEG: from structure-property relationships to better-defined therapeutic. Polym Chem 2011, 10.1039/c0py00406e.
36. Samad A., Alam M.I., Saxena K. Dendrimers: a class of polymers in the nanotechnology for the delivery of active pharmaceuticals. Curr Pharm Des 2009, 15:2958-2969.
37. Montero de Espinosa L., Meier M.A. Synthesis of star- and block-copolymers using ADMET: head-to-tail selectivity during step-growth polymerization. Chem Commun (Camb) 2011, 47:1908-1910.
38. Carlmark A., Hawker C., Hult A., Malkoch M. New methodologies in the construction of dendritic materials. Chem Soc Rev 2009, 38:352-362.
39. van Dijk M., Rijkers D.T., Liskamp R.M., van Nostrum C.F., Hennink W.E. Synthesis and applications of biomedical and pharmaceutical polymers via click chemistry methodologies. Bioconjug Chem 2009, 20:2001-2016.
40. Qiu L.Y., Bae Y.H. Polymer architecture and drug delivery. Pharm Res 2006, 23:1-30.
41. Merschky M., Wyszogrodzka M., Haag R., Schmuck C. pH-triggered self-assembly of zwitterionic polyglycerol dendrons into discrete and highly stable supramolecular dendrimers in water. Chemistry 2010, 16:14242-14246.
42. Viegas T.X., Bentley M.D., Harris J.M., Fang Z., Yoon K., Dizman B., Weimer R., Mero A., Pasut G., Veronese F.M. Polyoxazoline: chemistry, properties, and applications in drug delivery. Bioconjug Chem 2011, 10.1021/bc200049d.
43. Besheer A., Hertel T.C., Kressler J., Mader K., Pietzsch M. Enzymatically catalyzed HES conjugation using microbial transglutaminase: proof of feasibility. J Pharm Sci 2009, 98:4420-4428.
44. Biricova V., Laznickova A. Dendrimers: analytical characterization and applications. Bioorg Chem 2009, 37:185-192.
45. Paul A., Vicent M.J., Duncan R. Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates. Biomacromolecules 2007, 8:1573-1579.
46. Charlton C., Gubala V., Gandhiraman R.P., Wiechecki J., Le N.C., Coyle C., Daniels S., Maccraith B.D., Williams D.E. TIRF microscopy as a screening method for non-specific binding on surfaces. J Colloid Interface Sci 2011, 354:405-409.
47. Barz M., Canal F., Koynov K., Zentel R., Vicent M.J. Synthesis and in vitro evaluation of defined HPMA folate conjugates: influence of aggregation on folate receptor (FR) mediated cellular uptake. Biomacromolecules 2010, 11:2274-2282.
48. Lurie D.J., Mader K. Monitoring drug delivery processes by EPR and related techniques - principles and applications. Adv Drug Deliv Rev 2005, 57:1171-1190.
49. Burks S.R., Macedo L.F., Barth E.D., Tkaczuk K.H., Martin S.S., Rosen G.M., Halpern H.J., Brodie A.M., Kao J.P.Y. Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells. Breast Cancer Res Treat 2010, 124:121-131.
50. Kempe S., Metz H., Mader K. Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process. J Control Release 2008, 130:220-225.
51. Duncan R. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev 2009, 61:1131-1148.
52. Duncan R., Vicent M.J. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev 2010, 62:272-282.